{
    "clinical_study": {
        "@rank": "11447", 
        "acronym": "EXPLAIN", 
        "arm_group": {
            "arm_group_label": "unselected Fragile-X patients"
        }, 
        "brief_summary": {
            "textblock": "This prospective observational study (registry) on Fragile X syndrome (FXS)  is designed to\n      evaluate characteristics, management  and patient and caregiver-related outcomes  the\n      quality of life of Families and patients with FXS and to collect epidemiological and health\n      economic data.\n\n        -  EXPLAIN  will report current and comprehensive data onEpidemiology data on fragile X\n           syndrome\n\n        -  Characterisation of the phenotype of FXS patients\n\n        -  Description of patient characteristics (demographics, family history, comorbidity,\n           education, working situations, care situations, insurance status)\n\n        -  Documentation of therapeutic interventions\n\n        -  Recording and assessment of psychosocial parameters (possibly also inclusion of family\n           members, carers)\n\n        -  quality of life of the carer and if possible the patient\n\n        -  Health economic parameters and consumption of resources"
        }, 
        "brief_title": "EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Fragile-X Syndrome", 
        "condition_browse": {
            "mesh_term": "Fragile X Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with FXS as confirmed by genetic testing\n\n        Exclusion Criteria:\n\n          -  none\n\n          -  Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with fragile-X Syndrome"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711606", 
            "org_study_id": "CAFQ056BDE-EPI-01"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fragile-X Syndrome", 
            "registry", 
            "non-interventional trial", 
            "patient-related outcome study", 
            "drug utilization", 
            "effectiveness", 
            "treatment patterns", 
            "patient characteristics under real life conditions", 
            "quality of life", 
            "economics"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "last_name": "Marc Brinkman"
            }, 
            "facility": {
                "address": {
                    "city": "Nuremberg", 
                    "country": "Germany"
                }, 
                "name": "Novartis Investigative site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "EXPLAIN - FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes", 
        "overall_contact": {
            "last_name": "Marc Brinkman", 
            "phone": "+49 911 273 12102"
        }, 
        "overall_official": {
            "affiliation": "Klinik f\u00fcr Psychiatrie, Neurologie, Psychosomatik und Psychotherapie im Kindes- und Jugendalter, Gehlsheimer Stra\u00dfe 20, D- 18147 Rostock", 
            "last_name": "Frank H\u00e4ssler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Ethics Commission", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Patient characteristics (demographics, family history, comorbidities, education, working situation, care situation, insurance status)", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711606"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Epidemiology data on Fragile X Syndrome (FXS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Health-economic parameters and consumption of resources", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Therapeutic interventions and their application rationale", 
                "safety_issue": "No", 
                "time_frame": "3 Years"
            }, 
            {
                "measure": "Psychosocial parameters (poss. also inclusion of family members, caregivers)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Quality of life of the caregiver and possibly the patient", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}